With an FDA decision drawing near for testosterone gel Fortesta, Endo Pharmaceuticals Inc. has grabbed marketing rights to the hormone replacement therapy in the U.S. under a deal valued at up to $210 million with U.K.-based Prostrakan Group plc. (BioWorld Today)

New York-based Forest Laboratories Inc. and Swiss drugmaker Glenmark Pharmaceuticals SA reported disappointing top-line results from a Phase IIb dose range-finding study of oglemilast in patients with chronic obstructive pulmonary disease (COPD). (BioWorld Today)